Pakistan Medicines & Pharma IntelligenceMedicine data  •  Company portfolios  •  Price records
MedInfoBaseMedicines · Evidence · Intelligence
Home / Pharmaceutical company intelligence
Pharmaceutical company intelligence

MTI MEDICAL (PVT.) LTD

Pharmaceutical manufacturer · Pakistan

Database-driven profile Portfolio, price and regulatory-source intelligence derived from MedInfoBase records.
ShareSend this page
Regulatory & corporate identity

Company profile

Not yet verified
Company type
Pharmaceutical manufacturer
DRAP-linked licence identifiersShown as recorded in linked source rows; not a claim of current validity.
DML 000801 59 linked products · source seen 10 Aug 2026 View source ↗
Location intelligence

Company location

Google Maps
Exact site not yet verified

MedInfoBase will not invent a factory or office location. The map appears after a sourced address, Place ID or verified embed URL is added.

Open in Google Maps ↗ The Google Maps search link uses the company name and available city/country context; it is not presented as a verified premises pin.
Intelligence snapshot

Portfolio at a glance

Not sales data · current MedInfoBase database view
Rx59product presentations
G32generic molecules
DF7dosage-form groups
TA8therapeutic areas
PKR59current price records
REG53registration numbers
Data coverage

How complete is this profile?

Current price coverage100%
products with a current official price
Source-linked coverage100%
products linked back to a source record
Unit-price parse coverage86%
priced packs safely normalized per unit
Comparable-market coverage78%
products with at least one like-for-like comparator
Therapeutic classification100%
products assigned to a broad therapeutic area
Visual intelligence

Downloadable company intelligence charts

Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.

Shareable intelligence

Therapeutic Portfolio Mix

Shows where the company portfolio is concentrated across broad therapeutic areas.

Therapeutic Portfolio MixMTI MEDICAL (PVT.) LTDShare of current product presentations by broad therapeutic areaMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/mti-medical-pvt-ltdGenerated 10 Aug 2026Anti-infectives41 · 69%Gastrointestinal & hepatology6 · 10%Pain & musculoskeletal5 · 8%Cardiovascular2 · 3%Respiratory & allergy2 · 3%Anesthesia & critical care1 · 2%Reproductive & genitourinary1 · 2%Other therapeutic areas1 · 2%Percentages are based on current product presentations in the MedInfoBase company portfolio.

Portfolio distribution, not sales or market-share data.

Shareable intelligence

Dosage Form Portfolio

Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.

Dosage Form PortfolioMTI MEDICAL (PVT.) LTDDistribution of current product presentations by normalized dosage formMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/mti-medical-pvt-ltdGenerated 10 Aug 202659presentationsInjection29 · 49%Tablet14 · 24%Suspension8 · 14%Capsule4 · 7%Solution2 · 3%Drops1 · 2%Other forms1 · 2%Dosage-form wording is normalized for intelligence display; original source wording remains preserved in product records.

Counts are product presentations, not production or sales volumes.

Shareable intelligence

Equivalent-Market Price Position

Shows whether safely comparable products are below, near or above the market median unit price.

Equivalent-Market Price PositionMTI MEDICAL (PVT.) LTDCurrent company products compared with like-for-like equivalent medicines using normalized unit pricesMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/mti-medical-pvt-ltdGenerated 10 Aug 202646comparable productsBelow market median32 · 70%Near market median9 · 20%Above market median5 · 11%Company median price position-6.7%Lowest-price equivalents3Method: same generic + stated strength + dosage form + compatible unit basis; pack prices normalized per unit.

This is price-position intelligence, not sales, demand or market-share data.

Shareable intelligence

Closest Portfolio Competitors

Highlights other manufacturers with the greatest generic overlap with this company portfolio.

Closest Portfolio CompetitorsMTI MEDICAL (PVT.) LTDCompanies with the largest number of shared generic medicines in the MedInfoBase databaseMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/mti-medical-pvt-ltdGenerated 10 Aug 2026Pharmasol (Pvt) Ltd.25 shared78% overlapNabiqasim Industries (Pvt) Ltd.,24 shared75% overlapS.J & G. Fazul Ellahie (pvt) limite…24 shared75% overlapM/s. Genix Pharma (Pvt) Ltd.23 shared72% overlapMacter International Limited23 shared72% overlapNeutro Pharma (Pvt.) Ltd.,23 shared72% overlapPortfolio overlap measures shared generics only; it is not a measure of market share, affiliation or sales competition.

Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.

Portfolio intelligence

Therapeutic areas

Broad portfolio view

High-level clinical areas represented by this company’s current MedInfoBase portfolio.

Anti-infectives41 products · 69%
Gastrointestinal & hepatology6 products · 10%
Pain & musculoskeletal5 products · 8%
Cardiovascular2 products · 3%
Respiratory & allergy2 products · 3%
Anesthesia & critical care1 products · 2%
Reproductive & genitourinary1 products · 2%
Hematology & thrombosis1 products · 2%
Pharmacological detail

Drug classes

More specific view

More specific classes derived from the canonical generic and preserved curated classifications.

Third-generation cephalosporins11 products · 19%
Fluoroquinolone antibacterials6 products · 10%
Analgesics / NSAIDs5 products · 8%
Macrolide antibacterials5 products · 8%
Antifungals3 products · 5%
Antivirals3 products · 5%
Proton pump inhibitors3 products · 5%
Laxatives2 products · 3%
Formulation footprint

Dosage forms

Injection29 products
Tablet14 products
Suspension8 products
Capsule4 products
Solution2 products
Drops1 products
Syrup1 products
How MedInfoBase classifies the portfolio

MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.

Portfolio leaders

Deepest brand families

Ranked by registered presentations · not sales
#1 CytozonCeftriaxone 6presentations 1 g, 2 g, 250 mg, 500 mg · Injection #2 CytoCiprofloxacin 3presentations 250 mg, 250 mg/5 mL, 500 mg · Tablet, Suspension #3 MizecCefotaxime 3presentations 1 g, 250 mg, 500 mg · Injection #4 PrufieIbuprofen 3presentations 100 mg/5 mL · Suspension #5 ZecmoAzithromycin 3presentations 200 mg/5 mL, 250 mg, 500 mg · Suspension, Capsule, Tablet #6 ApholacLactulose 2presentations 3.35 g/5 mL · Solution
Price intelligence

Unit-price positioning vs equivalent products

Same generic + strength + form + unit basis
Below market median3270% of comparable products
Near market median9within ±5% of median
Above market median511% of comparable products
Lowest-price equivalents3ties included
Company median price position -6.7% relative to the median unit price of like-for-like equivalent products.
Most competitively positioned examplesProducts with at least 3 market comparators
Simvaton 20 mgSimvastatin · Tablet · 10's PKR 27.90/tablet-38.2% vs market median Tazoprid 2 g + 0.25 gPiperacillin + tazobactam · Powder for injection · 1's PKR 559.54/vial/unit-18.7% vs market median Lorantex 5 mg/5 mLLoratadine · Syrup · 60ml PKR 1.44/mL-13.9% vs market median Cyto 250 mg/5 mLCiprofloxacin · Suspension · 60ml PKR 4.39/mL-13.4% vs market median Cyto 500 mgCiprofloxacin · Tablet · 10's PKR 37.20/tablet-11.5% vs market median
How MedInfoBase calculates price position

Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.

Competitive landscape

Portfolio overlap

Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.

Pharmasol (Pvt) Ltd.251 products · 101 generics 25shared generics Nabiqasim Industries (Pvt) Ltd.,362 products · 118 generics 24shared generics S.J & G. Fazul Ellahie (pvt) limited.193 products · 68 generics 24shared generics M/s. Genix Pharma (Pvt) Ltd.290 products · 97 generics 23shared generics Macter International Limited248 products · 91 generics 23shared generics Neutro Pharma (Pvt.) Ltd.,210 products · 97 generics 23shared generics
Regulatory & price activity

Observed database signals

Registration numbers53
Price-history records64
Products with price history4
Source records with multiple versions0
Latest MedInfoBase verification9 Aug 2026
Latest effective price date24 Sep 2025
Latest source observation10 Aug 2026

These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.

Sponsored company campaign area · advertising must be clearly disclosed
Complete company portfolio

Products and presentations

59 results
Reset
BrandGenericStrengthFormPackRegistrationOfficial priceUnit priceMarket position
Amphotericin B Amphotericin B 50 mg Lyophilized powder for injection 1's 119308 PKR 1,285.59 PKR 1,285.59/vial/unit Near median
Antamin Ketamine 500 mg Injection 10ml* 1's vial 081866 PKR 190.33 — No comparator
Apholac Lactulose 3.35 g/5 mL Oral solution 120ml 097595 PKR 256.08 PKR 2.13/mL Near median
Apholac Lactulose 3.35 g/5 mL Oral solution 240ml 097595 PKR 484.48 PKR 2.02/mL Near median
Arpes Aciclovir 250 mg Injection Lyophilized 1's vial 084916 PKR 674.81 — No comparator
Bactidim Ceftazidime 1 g Injection 1's vial 084907 PKR 427.39 PKR 427.39/vial/unit 6% below median
Bactidim Ceftazidime 250 mg Injection 1's vial 084905 PKR 149.58 PKR 149.58/vial/unit 6% below median
Celsius Paracetamol 120 mg/5 mL Suspension 60ml 081853 PKR 62.91 PKR 1.05/mL Near median
Celsius Paracetamol 120 mg Suspension 100ml 081853 PKR 104.84 PKR 1.05/mL Near median
Clomate Clomifene citrate 50 mg Tablet 10's 091802 PKR 373.74 PKR 37.37/tablet 9% below median
Colimate Colistimethate sodium 1 MIU Injection 1's 097779 PKR 1,143.33 PKR 1,143.33/vial/unit Near median
Cyto Ciprofloxacin 500 mg Tablet 10's 078864 PKR 372.01 PKR 37.20/tablet 11% below median
Cyto Ciprofloxacin 250 mg/5 mL Suspension 60ml 105972 PKR 263.31 PKR 4.39/mL 13% below median
Cyto Ciprofloxacin 250 mg Tablet 10's 078863 PKR 224.94 PKR 22.49/tablet 11% below median
Cytozon Ceftriaxone 2 g IV injection 1's vial 084896 PKR 778.62 PKR 778.62/vial/unit 7% below median
Cytozon Ceftriaxone 500 mg IV injection 1's vial 084898 PKR 294.15 PKR 294.15/vial/unit 6% below median
Cytozon Ceftriaxone 250 mg IV injection 1's vial 084899 PKR 174.75 PKR 174.75/vial/unit 6% below median
Cytozon Ceftriaxone 1 g IV injection 1's vial 084897 PKR 555.42 PKR 555.42/vial/unit 6% below median
Cytozon Ceftriaxone 500 mg IM injection 1's vial 084900 PKR 294.15 PKR 294.15/vial/unit 10% below median
Cytozon Ceftriaxone 250 mg IM injection 1's vial 084901 PKR 174.75 PKR 174.75/vial/unit 11% below median
MedInfoBase company-intelligence methodology

This page is generated from MedInfoBase medicine, generic, company, price and DRAP-source records. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.

Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.